Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
10 oct. 2024 07h00 HE
|
Avacta Group
10 October 2024 Avacta Group plc(“Avacta” or “the Group” or “the Company”) Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024...
Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
10 oct. 2024 02h00 HE
|
Avacta Group
10 OctoberAvacta Group plc(“Avacta” or “the Group” or “the Company”)Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium...
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
14 oct. 2023 12h30 HE
|
Coherus BioSciences, Inc.
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with...
Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference
11 oct. 2023 12h00 HE
|
Quanta Therapeutics, Inc.
The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.
Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
05 oct. 2023 02h00 HE
|
Avacta Group
5 October 2023 Avacta Group plc (“Avacta” or the “Group” or the “Company”) Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International...